Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | HTR2C | P28335 | 1/20 | 0.80 |
| ▸ | HRH1 | P35367 | 1/20 | 0.80 |
| ▸ | HTR2B | P41595 | 1/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.80 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7928871 | 1.00 | TACR1 (0.81) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL502157 | 1.00 | TACR1 (0.81) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL3471040 | 1.00 | TACR1 (0.81) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7225876 | 0.99 | TACR1 (0.81) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL7933491 | 0.92 | TACR1 (0.69) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL7933495 | 0.91 | TACR1 (0.69) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4918415 | 0.91 | TACR1 (0.86) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL4915848 | 0.91 | TACR1 (0.86) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL4918599 | 0.90 | TACR1 (0.85) | TACR1CYP2D6KCNH2HTR1AHTR2A | |
| SCHEMBL8458282 | 0.90 | TACR1 (1.00) | TACR1CYP2D6KCNH2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030215456-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2003-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030215456-A1 | Method of treating cancer | TACR1, TACR2, KLK3 | TACR1 1/4885CYP2D6 3635/4885KCNH2 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.